Market Intelligence, Clinical Progress, and High-Purity Reagents for Prostate Cancer & Gastrointestinal Stromal Tumor (GIST) Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ETV1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ETV1 Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Ideal for DNA-binding and PPI assays. |
View ETV1 Products |
| Gene Delivery | ETV1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and reporter gene assays. |
View ETV1 Products |
| Benchmark Ab | Anti-ETV1 Recombinant Antibody Recombinant positive control for ChIP, Western Blot, and IHC validation. |
View ETV1 Products |
| Validator | ETV1 siRNA Set For target knockdown and specificity verification in phenotypic assays. |
View ETV1 Products |
| Related Target A | KIT Synergistic master regulator in Gastrointestinal Stromal Tumors (GIST); co-regulates oncogenic transcription. |
View KIT Products |
| Related Target B | ERG ETS family homolog; critical counter-screening target for small molecule selectivity assays. |
View ERG Products |
| Related Target C | AR | View AR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular Localization & PPI Screening | Sequence-verified full-length ETV1 proteins optimized for protein-protein interaction (PPI) and transcription complex assembly assays. |
| ETS Family Cross-Reactivity / Off-Target Risks | Homolog screening panel including high-purity ERG, ETV4, and ETV5 proteins strictly verified by mass spectrometry. |
| Lack of Standard Reference Controls | Sequence-defined recombinant benchmark antibodies available for Western Blot, ELISA, and chromatin immunoprecipitation (ChIP) controls. |
| Phenotypic Validation False Positives | Validated siRNA sets included to confirm ETV1-dependency in cancer cell lines. |
Live ETV1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ETV1 therapeutics is intensifying, with major players shifting focus from traditional indirect pathway modulation to direct protein-protein interaction (PPI) inhibitors and targeted protein degradation (PROTACs). As first-generation direct inhibitors reach preclinical and early clinical validation, the next wave of R&D is targeting drug-resistant fusions and synergistic combinations with tyrosine kinase inhibitors (TKIs).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI / DNA-binding Inhibitors) | Academic Consortia, Biotech Startups | Prostate Cancer, GIST | High-purity recombinant ETV1 for biochemical binding and EMSA assays. |
| Targeted Protein Degradation (PROTACs) | Oncology-focused Biotechs | TKI-resistant GIST, Melanoma | Full-length ETV1 protein for ternary complex formation and ubiquitination assays. |
| Combination Therapies (with KIT/AR inhibitors) | Global Pharmaceutical Corporates | Refractory Solid Tumors | Lentivirus-mediated stable cell lines expressing ETV1 fusions for synergistic screening. |